In this guest post by Drs. Nidhi Madan and Annabelle Volgman discuss why early detection of AFib can lead to a significant reduction of risk.
Nidhi Madan, MD, MPH; Annabelle S. Volgman, MD, FACC, FAHA
Atrial fibrillation (AFib) is the most common cardiac arrhythmia, with its prevalence projected to increase from 5.2 million in 2010 to 12.1 million cases in 2030 in the United States.1 AFib confers a higher risk of stroke, heart failure, cognitive decline and mortality.2,3 Early identification of AFib is imperative to reduce morbidity and mortality. Several factors cause structural and electrical remodeling of the atria resulting in AFIB. Established non-modifiable risk factors for AFib include advanced age and male sex. Female sex is a risk factor for strokes for patients with AFib. Other modifiable risk factors include smoking, alcohol use, obesity, diabetes, hypertension, sleep apnea, myocardial infarction, valve disease and heart failure.
PPAHS is proud to support and participate in WomenHeart’s National AFib Month Screening Campaign. PPAHS asks clinicians to please screen for AFib.
By WomenHeart (WomenHeart: The National Coalition for Women with Heart Disease, is a nonprofit, 501(c)(3) patient advocacy organization with thousands of members nationwide, including women heart patients and their families, health care providers, advocates and consumers committed to helping women live longer, healthier lives. WomenHeart supports, educates and advocates on behalf of the nearly 48 million American women living with or at risk of heart disease.)
Studies show that early detection of AFib can reduce an individual’s risk of stroke by as much as 60 percent. WomenHeart: The National Coalition for Women with Heart Disease, is launching the “Nationwide AFib Month Opportunistic Screening Initiative.”
Anticoagulants (more commonly referred to as blood thinners) are routinely used to treat, prevent and reduce the risk of venous thromboembolism (VTE), which consists of prevent deep vein thrombosis (DVT) and pulmonary embolism (PE).
According to World Thrombosis Day, 1 in 4 people worldwide are dying from conditions caused by thrombosis:
How to Prevent Deadly Blood Clots: Three Free Resources from the Physician-Patient Alliance for Health & Safety
World Thrombosis Day asks us to be aware of tips to prevent deadly blood clots:
When you think of potentially deadly health issues, do you think of a blood clot? According to a recent U.S. survey, only 7 percent of people say they are concerned about blood clots, known by the medical term thrombosis. However, what they might not know is one in four people worldwide die from conditions caused by thrombosis, making it a leading cause of global death and disability.
In honor of WTD 2017, the Physician-Patient Alliance for Health & Safety believes that blood clots safety consists of four steps: Read More
Patient advocates and leading medical societies involved in awareness building and improving patient safety in Atrial Fibrillation (Afib) and venous thromboembolism (VTE) gathered recently for the 1st Annual Anticoagulation Summit, a two-day conference.
Michael Wong, JD, founder and Executive Director of the Physician-Patient Alliance for Health & Safety (PPAHS), presented a poster on the OB VTE Safety Recommendations, which were released by PPAHS, in collaboration with the Institute for Healthcare Improvement and the National Perinatal Association. The recommendations, compiled by a panel of health experts, give clinicians a step-by-step checklist to help assess all OB patients’ risks for VTE and identify the appropriate prophylaxis regimen to improve health outcomes for maternal patients. Read More
March is Blood Clot Awareness Month.
Spearheaded by the National Blood Clot Alliance, #BCAM is a time for patients, caregivers, healthcare professionals, and advocates to draw attention to deep vein thrombosis and venous thromboembolism.
According to the National Blood Clot Alliance:
“Blood clots do not discriminate. They can and do affect anyone from children to senior citizens, from professional athletes to mothers, women and men – no one is immune. Tragically, roughly 274 lives are lost each day in the U.S. simply because public awareness about life-threatening blood clots is so low.”
Blood Clot Awareness Month is a time for us to highlight stories and resources that you can share with colleagues, patients, and loved ones to bring attention to blood clots. Read More
The Physician-Patient Alliance for Health & Safety (PPAHS) released findings on practical solutions to prevent venous thromboembolism (VTE) in patients undergoing hip and knee replacement from its Orthopedic VTE Report.
The Physician-Patient Alliance for Health & Safety (PPAHS) released findings on practical solutions to prevent venous thromboembolism (VTE) in patients undergoing hip and knee replacement in its Orthopedic VTE Safety Report.
The survey gathered 41 respondents from across the United States and targeted experts in orthopedics. The majority of respondents indicated that they were either physicians (42.5%) or nurses (32.5%). Those who elected to identify themselves as “Other” largely fell within four self-identified professions: nurse practitioners, physical therapists, program managers, and pharmacists. About 3 in 5 respondents indicated that their primary work setting was in Orthopedics.
The following is an excerpt of an article on bundled payments for joint replacement written by Michael Wong, JD, Executive Director of PPAHS and Lynn Razzano, RN, MSN, ONCC, Clinical Nurse Consultant at PPAHS. It was first appeared on The Doctor Weighs In on November 18, 2016. To read the full article, please click here.
The Physician-Patient Alliance for Health & Safety has been invited to become a partner of World Thrombosis Day, an international multi-organizational campaign devoted to increasing global awareness about thrombosis, including its causes, risk factors, signs/symptoms, evidence-based prevention and treatments.
World Thrombosis Day aims to highlight the need for action on thrombosis, specifically underscoring the unrecognized threat and serious consequences (morbidity and mortality) related to venous thromboembolism (VTE).